Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001092771 | SCV001249424 | pathogenic | not provided | 2019-05-01 | criteria provided, single submitter | clinical testing | |
Kariminejad - |
RCV001814003 | SCV001755173 | likely pathogenic | Abnormality of the nervous system | 2021-07-10 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000019615 | SCV003439193 | pathogenic | Pyridoxine-dependent epilepsy | 2023-04-19 | criteria provided, single submitter | clinical testing | This variant is also known as 1512delG. This frameshift has been observed in individuals with pyridoxine-dependent epilepsy (PMID: 16491085, 27186704). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change results in a frameshift in the ALDH7A1 gene (p.Ala533Profs*18). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 7 amino acid(s) of the ALDH7A1 protein and extend the protein by 10 additional amino acid residues. ClinVar contains an entry for this variant (Variation ID: 17999). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this frameshift affects ALDH7A1 function (PMID: 16491085). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. |
Genome- |
RCV000019615 | SCV004049940 | likely pathogenic | Pyridoxine-dependent epilepsy | 2023-04-11 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000019615 | SCV000039913 | pathogenic | Pyridoxine-dependent epilepsy | 2006-03-01 | no assertion criteria provided | literature only |